Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Selincro

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
  • Y. Tadori
  • Nihon yakurigaku zasshi. Folia pharmacologica…
  • 2020
  • Corpus ID: 211726945
Nalmefene (Selincro®), an opioid receptor modulator, is approved in Japan, the European Union, and other countries for reducing… 
2016
2016
AIMS To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
The opioid antagonist nalmefene (selincro®) was approved for alcohol‐related disorders by the European Medicines Agency in 2013… 
2016
2016
Introduction Nalmefene (NMF – SELINCRO®), a drug for alcohol withdrawal management (AWM), is both a partial agonist and an… 
Review
2015
Review
2015
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the… 
  • table 1
2015
2015
Case 1 A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of… 
2015
2015
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of… 
Review
2014
Review
2014
  • D. Spence
  • BMJ : British Medical Journal
  • 2014
  • Corpus ID: 38653312
Both Glasgow and medical school were hard drinking gigs. I enjoy alcohol and drink it for its psychoactive effect rather than for… 
2014
2014
The opioid system modulator nalmefene (Selincro®) is the first pharmacological therapy to be approved in the EU to reduce alcohol… 
Review
2013
Review
2013
The opioid system modulator nalmefene (Selincro®) is approved in the EU for as-needed use to reduce alcohol consumption in… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4